Alzheimer's could be halted with treatment which eliminates immune cells

Researchers at Washington University experimented on mice to discover that microglia kill neurons in the brain, accelerating the rate of brain damage.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

Publication date: Available online 21 October 2019Source: NeuroImageAuthor(s): Clément Abi Nader, Nicholas Ayache, Philippe Robert, Marco Lorenzi, Alzheimer's Disease Neuroimaging InitiativeAbstractWe introduce a probabilistic generative model for disentangling spatio-temporal disease trajectories from collections of high-dimensional brain images. The model is based on spatio-temporal matrix factorization, where inference on the sources is constrained by anatomically plausible statistical priors. To model realistic trajectories, the temporal sources are defined as monotonic and time-reparameterized Gaussian Processe...
Source: NeuroImage - Category: Neuroscience Source Type: research
Publication date: Available online 21 October 2019Source: Life SciencesAuthor(s): Hang Wu, Zhi-gang Wu, Wen-jing Shi, Hui Gao, Hong-hai Wu, Fang Bian, Peng-peng Jia, Yan-ning HouAbstractAims: Alzheimer's disease (AD) is closely related to abnormal glucose metabolism in the central nervous system. Progesterone has been shown to have obvious neuroprotective effects in the pathogenesis of AD, but the specific mechanism has not been fully elucidated. Therefore, the purpose of this study was to investigate the effect of progesterone on the glucose metabolism of neurons in amyloid precursor protein (APP)/presenilin 1 (PS1) mice ...
Source: Life Sciences - Category: Biology Source Type: research
Shares of Biogen Inc. were up more than 40 percent Tuesday morning after the Cambridge drugmaker said it will file for approval of an Alzheimer's drug seven months after discontinuing development of that same drug. Biogen (Nasdaq: BIIB) announced Tuesday morning, shortly before its third-quarter earnings report, that "based on discussions with the FDA," the company will submit an application for approval of aducanumab to the Food and Drug Administration "in early 2020." Biogen said that the application…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Source Type: news
In an analyst note following the news, R.W. Baird ’s Brian Skorney wrote that it is “highly unlikely” that the drug will ultimately be approved. Nevertheless, the Cambridge company's stock rose 36 percent as of 10 a.m., adding $17 billion to the company's market cap.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Shares of Biogen Inc. were up more than 40 percent Tuesday morning after the Cambridge drugmaker said it will file for approval of an Alzheimer's drug seven months after discontinuing development of that same drug. Biogen (Nasdaq: BIIB) announced Tuesday morning, shortly before its third-quarter earnings report, that "based on discussions with the FDA," the company will submit an application for approval of aducanumab to the Food and Drug Administration "in early 2020." Biogen said that the application…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Source Type: news
Source: Jornal Brasileiro de Psiquiatria - Category: Psychiatry Source Type: research
Conclusion Cognitive rehabilitation is able to prolong the independence of the patient in performing activities of daily living and generate functional and structural changes. As a consequence of the finding of few studies that met the eligibility criteria, we also verified the need for more controlled studies and greater application control, considering the high risk of bias in the studies used.
Source: Jornal Brasileiro de Psiquiatria - Category: Psychiatry Source Type: research
Conclusions Nuclear transcription receptors, cerebral cortex and hippocampus, microglia, and amyloid beta protein have shown significant importance in the pathogenesis of Alzheimer ’ s disease in this study.
Source: Jornal Brasileiro de Psiquiatria - Category: Psychiatry Source Type: research
Source: Clinical Interventions in Aging - Category: Geriatrics Tags: Clinical Interventions in Aging Source Type: research
This article reviews advances in the diagnosis, epidemiology, pathology, hypothesized etiopathogenesis, and biomarkers and disease-modifying therapeutic approaches of PSP that is leading it to become a frontrunner in translation.
Source: Frontiers in Neurology - Category: Neurology Source Type: research
More News: Alzheimer's | Brain | Health | Neurology | Washington University